@entity10099 in chronic XXXX . Results of a six month controlled multicenter study using @entity10099 tablets 200 mg.

@entity1 @entity455 @entity66 @entity10099 @entity613 @entity158
The study was carried out on @entity1 with @entity613 (Fontaine's stage II). The arterial and @entity66 was confirmed and localized by angiography or Doppler velocimetry examination. One hundred eighty-six @entity1 were selected initially. Their @entity158 -free walking distance on a treadmill (at a speed of 3 km/hour and an inclination of 10%) had to be 150-300 m. During the first month all @entity1 received 3 placebo tablets daily. At the end of this run-in period (D-30; D 0) and after checking walking distance stability (allowed variation: +/- 20% between the two measurements) the @entity1 were included in the study. One hundred fifty-four @entity1 were selected and 118 remained during the whole study. The study was designed as a double-blind, using two parallel randomly selected groups. Sixty-four @entity1 received for six months @entity10099 (3 X 200 mg tablets daily with meals); 54 @entity1 received placebo under the same conditions. During this period, clinical and paraclinical examinations were carried out every quarter (D 90 and D 180). After checking the initial homogeneity of the @entity10099 and placebo-groups, the comparison between groups indicates a significant improvement in @entity10099 group after 3 and 6 months of treatment. At the end of the study the observed differences in walking distance with @entity10099 are approximately twice the difference in the reference group (D 90: p less than 0.05; D 180: p less than 0.02). The results of this study indicate that @entity10099 is an efficient pharmacological tool for treatment of @entity1 with chronic @entity455 (Fontaine's stage II).
